Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 20/20 | 0.67 |
| ▸ | MERTK | Q12866 | 20/20 | 0.67 |
| ▸ | TYRO3 | Q06418 | 19/20 | 0.67 |
| ▸ | MET | P08581 | 18/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561254 | 0.99 | AXL (0.67) | AXLMERTKTYRO3MET | |
| Hydrochloric Acid SCHEMBL1945556 | 0.99 | AXL (0.67) | AXLMERTKTYRO3MET | |
| Hydrochloric Acid SCHEMBL1945171 | 0.92 | AXL (0.67) | AXLMERTKTYRO3MET | |
| SCHEMBL12561658 | 0.92 | AXL (0.68) | AXLMERTKTYRO3MET | |
| Hydrochloric Acid SCHEMBL1944278 | 0.91 | AXL (0.67) | AXLMERTKTYRO3MET | |
| SCHEMBL12561364 | 0.91 | AXL (0.67) | AXLMERTKTYRO3MET | |
| SCHEMBL12561666 | 0.91 | AXL (0.67) | AXLMERTKTYRO3MET | |
| Hydrochloric Acid SCHEMBL1945173 | 0.91 | AXL (0.67) | AXLMERTKTYRO3MET | |
| Hydrochloric Acid SCHEMBL1945166 | 0.91 | AXL (0.67) | AXLMERTKTYRO3MET | |
| SCHEMBL13905992 | 0.89 | AXL (0.55) | AXLMERTKTYRO3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-2193130-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009033084-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | AXL 43/4885MERTK 63/4885TYRO3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.